Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: Results from an observational study

Corinne Haioun, Antonio Salar, Ruth Pettengell, Hans Erik Johnsen, Ulrich Duehrsen, Francesca Gaia Rossi, Gregor Verhoef, Matthias Schwenkglenks, Ulrich Jaeger, Lisa Hamilton, Beatriz Pujol, Pieternella Johanna Lugtenburg

Research output: Contribution to journalArticlepeer-review

Abstract

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) ±° rituximab [(±°R)CHOP] is the current standard of care for aggressive non-Hodgkin lymphoma (NHL). Anemia resulting from chemotherapy can be treated with erythropoiesis-stimulating agents (ESAs). As part of the observational IMPACT NHL study, data were collected on ESA use and anemia-related outcomes in 1829 adults receiving (±°R)CHOP-14 or (±°R)CHOP-21. Overall, 33% of patients were anemic during chemotherapy. Older age, lower baseline hemoglobin (Hb), worse performance status, more advanced disease stage, and use of CHOP-14 were significant predictors of transfusion and anemia in logistic regression models. ESAs were received by 404 patients, usually in response to low or declining Hb levels. Most patients (65%) had Hb 9-11 g/dL at ESA initiation, and 89% (Kaplan-Meier percentage) achieved Hb 10-12 g/dL. In conclusion, two-thirds of anemic patients with NHL receiving (±°R)CHOP initiated ESA treatment at Hb 9-11 g/dL, and most achieved target Hb levels (10-12 g/dL).

Original languageEnglish
Pages (from-to)796-803
Number of pages8
JournalLeukemia and Lymphoma
Volume52
Issue number5
DOIs
Publication statusPublished - May 2011

Keywords

  • anemia
  • CHOP chemotherapy
  • erythropoiesis-stimulating agents
  • non-Hodgkin lymphoma
  • observational study

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: Results from an observational study'. Together they form a unique fingerprint.

Cite this